No Data
Weekly Buzz: So far, Santa is Letting us Down
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
10 Industrials Stocks With Whale Alerts In Today's Session
JPMorgan Says These 2 Value Stocks Are Among Its 'Best Idea' Picks for 2025
Everbright: Maintains the "Buy" rating for ASCLETIS-B. ASC47 combined with semaglutide shows superior effects.
Everbright released a research report stating that ASCLETIS-B (01672) is actively laying out its strategies in the MASH and weight loss sectors, and its progress is among the best in the country. Considering the company's effective control over various expenses, the net income forecast for 2024-2025 has been adjusted to -0.261/-0.313 billion yuan (previously -0.284/-0.34 billion yuan), and a new net income forecast for 2026 is -0.322 billion yuan, maintaining a "Buy" rating. The company released experimental data on the weight loss and muscle gain treatment drug ASC47 combined with semaglutide in obese mice; this drug is a fat-targeting, once-a-month subcutaneous injection of a thyroid hormone receptor β agonist.
Why the 'Dogs of the Dow' Stocks Just Might Deliver in 2025
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
